临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
6期
1050-1053
,共4页
瑞替普酶%尿激酶%溶栓%肺栓塞
瑞替普酶%尿激酶%溶栓%肺栓塞
서체보매%뇨격매%용전%폐전새
pulmonary thromboembolism%reteplase%urokinase%thrombolysis
目的:对比分析瑞替普酶与尿激酶溶栓治疗中危组肺栓塞临床疗效。方法根据不同的治疗方案将所有患者分成瑞替普酶组(23例)与尿激酶组(39例),将两组患者溶栓效果进行对比与分析。结果治疗后两组D-二聚体、肌钙蛋白T、N-ProBNP及PASP均较治疗前降低(P<0.05),PaO2较治疗前升高(P<0.05),两组患者治疗前与治疗后24小时D-二聚体及肌钙蛋白T差值无明显区别(P>0.05),但瑞替普酶组PaO2、N-ProBNP、PASP治疗前后差值明显大于尿激酶组(P<0.05)。结论瑞替普酶及尿激酶均可以用于治疗急性中危组PTE,但于住院期间给予中危组肺栓塞患者,瑞替普酶溶栓治疗效果优于尿激酶。
目的:對比分析瑞替普酶與尿激酶溶栓治療中危組肺栓塞臨床療效。方法根據不同的治療方案將所有患者分成瑞替普酶組(23例)與尿激酶組(39例),將兩組患者溶栓效果進行對比與分析。結果治療後兩組D-二聚體、肌鈣蛋白T、N-ProBNP及PASP均較治療前降低(P<0.05),PaO2較治療前升高(P<0.05),兩組患者治療前與治療後24小時D-二聚體及肌鈣蛋白T差值無明顯區彆(P>0.05),但瑞替普酶組PaO2、N-ProBNP、PASP治療前後差值明顯大于尿激酶組(P<0.05)。結論瑞替普酶及尿激酶均可以用于治療急性中危組PTE,但于住院期間給予中危組肺栓塞患者,瑞替普酶溶栓治療效果優于尿激酶。
목적:대비분석서체보매여뇨격매용전치료중위조폐전새림상료효。방법근거불동적치료방안장소유환자분성서체보매조(23례)여뇨격매조(39례),장량조환자용전효과진행대비여분석。결과치료후량조D-이취체、기개단백T、N-ProBNP급PASP균교치료전강저(P<0.05),PaO2교치료전승고(P<0.05),량조환자치료전여치료후24소시D-이취체급기개단백T차치무명현구별(P>0.05),단서체보매조PaO2、N-ProBNP、PASP치료전후차치명현대우뇨격매조(P<0.05)。결론서체보매급뇨격매균가이용우치료급성중위조PTE,단우주원기간급여중위조폐전새환자,서체보매용전치료효과우우뇨격매。
Objective To compare the efficacy of reteplase and urokinase in the treatment of medium-risk pulmonary thromboembolism ( PET ) . Methods 62 patients with medium-risk pulmonary thromboembolism were divided into two groups to be treated with reteplase (23 cases) and urokinase (39 cases). The effect of thrombolysis was compared. Results The levels of D-dimer, troponin T, NT-ProBNP, and PASP decreased (P<0. 05), and the level of PaO2 increased in both groups after the treatment (P<0. 05), but the difference was more pronounced in the reteplase group than in the urokinase group (P<0. 05). There was no significant difference in D-dimer and troponin T between the two groups before and 24-hour after the treatment (P>0. 05). Conclusion Both reteplase and uroki-nase are safe and effective in the treatment of acute medium-risk PTE, but the curative effect of reteplase is superior to urokinase.